Latest Conference Articles

Chovatiya discussed new data showing significant EASI improvements across moderate and severe atopic dermatitis.

Results from the phase 3 trial were published in NEJM and simultaneously presented as a late-breaking abstract at AAD 2026.

Marston discusses his sub analysis of the VESALIUS-CV trial, which indicated reduced MACE risk in patients with diabetes and no atherosclerosis after evolocumab treatment.

This interview with David Cotter, MD, PhD, highlights recent findings and new data in the psoriasis treatment space highlighted at AAD 2026.

CAR-T therapy in lupus may shift earlier in care, but challenges in access, logistics, and patient selection remain as the field moves toward precision treatment.

FSGS recurrence threatens transplant success, yet clinicians still lack reliable predictors, mechanisms, and effective prevention strategies.

New late-breaking phase 3 data suggest zasocitinib may help reshape the oral treatment landscape for moderate-to-severe plaque psoriasis.

Fearon discusses results from the ALL-RISE trial, which demonstrated the FFRangio’s efficacy in assessing lesions for patients with coronary artery disease.

Results of the MOMENTUM trial suggest the prevalence of hypercortisolism in resistant hypertension could be greater than previous estimates have indicated.

In this segment of his interview, Eichenfield highlights the safety and tolerability of roflumilast cream for children with atopic dermatitis in INTEGUMENT-OLE.

Hypertension drives millions of preventable deaths, yet control lags globally. The HEARTS framework offers practical, scalable solutions to close this gap.

The IMMpactful direct comparison provides prospective data in a moderate psoriasis population that previous MAICs could not fully capture.

Vlado Perkovic, MBBS, PhD, discusses APPLAUSE-IgAN data showing iptacopan reduced eGFR decline and lowered kidney event risk in IgA nephropathy.

Hiddo Heerspink, MD, PhD, highlights ASSIST trial data showing atrasentan reduced proteinuria by 25% on top of SGLT2 inhibitors in IgA nephropathy.

CAR-T therapy shows potential for deep, durable remission in lupus nephritis, but questions remain on safety, durability, and patient selection.

A subgroup analysis of VESALIUS-CV suggests evolocumab could have a role in prevention of primary events in some high-risk patients.

New data from the KARDINAL trial at ACC.26 provides insight, but raises questions regarding tonlamarsen and hypertension.

Sarma discusses the ongoing movement to highlight the different cardiovascular risks facing women, particularly during the most turbulent periods of life.

These 52-week, phase 3 data on icotrokinra, presented at AAD, highlight the drug's efficacy and safety among adults with moderate to severe plaque psoriasis.

The findings extend the radiographic dataset for risankizumab in PsA to 244 weeks — the longest such follow-up reported from the KEEPsAKE program.

Rosmarin discussed new late-breaking data from ADVANCE-AA at AAD 2026.

This late-breaking, phase 2 data highlights nemolizumab's clinically meaningful benefits for children with moderate-to-severe atopic dermatitis.

HI-PEITHO concluded use of ultrasound-facilitated catheter-directed fibrinolysis improves pulmonary embolism outcomes.

Soung discussed how new 52-week data support icotrokinra's recent FDA approval, marketed as Icotyde.

REMODEL offers new mechanistic insights into semaglutide, highlighting microvascular and endothelial effects that help explain its kidney and cardiovascular benefits.

KDIGO updates in IgA nephropathy highlight lower proteinuria targets, improved risk tools, and an expanding landscape of targeted and combination therapies.

This interview at AAD 2026 highlights Nguyen's views on the biggest drivers of patient dissatisfaction in dermatology practice settings.